Chiara Baratelli's research while affiliated with Ospedale Ordine Mauriziano di Torino, Umberto I and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (50)
Aim:
Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensure optimal care, especially in frail groups such as cancer patients (pts). This study investigated the efficacy of SARS-CoV-2 pre-procedure screening and...
e24014
Background: PROs are the gold standard to describe subjective symptoms. In order to improve clinical management of outpatients receiving active anti-cancer treatment at Medical Oncology, Mauriziano Hospital, Turin, Italy, in January 2018 we introduced in routine clinical practice an assessment of patient-reported symptoms and toxicities. We...
Purpose:
Medical records are a relevant source for real-world evidence. We introduced patient-reported outcomes (PROs) in clinical practice, demonstrating a significant quality-of-life improvement, compared to usual visit. In this secondary analysis, we describe the agreement between patients' and physicians' reports of 5 symptoms. Our hypothesis...
74
Background: While the management of nonmetastatic and oligometastatic rectal cancer has rapidly evolved over the last few decades, many grey areas and highly debated topics remain that foster significant variation in clinical practice. We aimed to identify controversial points and evidence gaps in this disease setting by systematically comparing...
Introduction
Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving active anti-cancer treatment, we introduced in routine cli...
Background:
While the management of nonmetastatic and oligometastatic rectal cancer has rapidly evolved over the last few decades, many grey areas and highly debated topics remain that foster significant variation in clinical practice. We aimed to identify controversial points and evidence gaps in this disease setting by systematically comparing r...
Background
Chemotherapy is the mainstay treatment for advanced biliary cancer (ABC). Best supportive care and clinical trials are currently alternative options. The identification of a prognostic score that can be widely applied to daily practice has the potential to better inform clinical management of ABC patients.
Methods
A cohort of 123 ABC pa...
Background:
Adenocarcinomas of the oral cavity are rare neoplasms, and only four cases of primary colonic adenocarcinoma of the tongue have ever been described in literature. Very few information about chemotherapy sensitiveness of this type of neoplasia is available, with only one regimen that showed some activity in a metastatic patient.
Case p...
According to current ESMO – MASCC guidelines, a combination of a neurokinin-1 receptor antagonist (NK1RA), dexamethasone and a 5-HT3 receptor antagonist (5-HT3RA) is recommended to prevent carboplatin-induced emesis, albeit with moderate level of confidence and not unanimous consensus. We performed a meta-analysis of randomized trials (RCTs) compar...
Background:
Targeted capture sequencing can potentially facilitate precision medicine, but the feasibility of this approach in gastrointestinal (GI) malignancies is unknown.
Patients and methods:
The FOrMAT (Feasibility of a Molecular Characterisation Approach to Treatment) study was a feasibility study enrolling patients with advanced GI malign...
The available fluoropyrimidines and oxaliplatin combinations for colorectal cancer patients have different safety profiles. The aim of this systematic review was to compare their toxicities.
The eligible studies were classified as: no bolus; 5-FU single bolus; 5-FU double bolus; capecitabine. We calculated the incidence of “any-grade” and “severe”...
Background:
The treatment of refractory metastatic colorectal cancer (rmCRC) and the lack of predictive variables are matters of debate.
Patients and methods:
We conducted a multicentre phase II trial assessing the disease control rate (DCR) of the combination of tegafur/uracil and mitomycin C in rmCRC. The number of previous lines of chemothera...
Background:
Refining the selection of metastatic colorectal cancer (mCRC) patients candidates for anti-EGFR monoclonal antibodies beyond RAS and BRAF testing is a challenge of precision oncology. Several uncommon genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than EGFR or downstream signaling pat...
Patients with RAS and wt mCRC are regarded as the best candidates to receive anti-EGFRs. Nevertheless, almost half of these patients do not achieve response, so that a deeper refinement of candidates’ selection would be highly desirable.
Different molecular alterations, supported by a strong and sound biologic rationale, have been suggested as pred...
Correlation between progression free survival (PFS) and overall survival (OS). (A) Correlation between differences in median values in all comparisons with available information (n=24). (B) Correlation between differences in median values in all comparisons with available information for anti-angiogenic drugs (n=16). (C) Correlation between differe...
Correlation between objective response rate (ORR) and overall survival (OS). (A) Correlation between differences in ORR and in median OS values in all comparisons with available information (n=25). (B) Correlation between differences in ORR and in median OS values in all comparisons with available information for anti-angiogenic drugs (n=16). (C) C...
11508
Background: Almost half of RAS and BRAFwt mCRC patients do not respond to anti-EGFRs. Different molecular alterations suggested as predictors of resistance have not been validated. Methods: We conducted a case-control study to prospectively demonstrate the negative predictive impact of HER-2 amplification or mutations (mut), MET amplification...
Background
The potential of chemotherapy as salvage treatment after failure of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective analysis to address this question.
Patients and Methods
Patients with newly diagnosed LARC who were inoperable or candidates for...
Background:
The optimal therapeutic strategy for metastatic colorectal cancer patients is still a matter of debate. There are no prognostic variables indicating how many lines individual patients ought to receive, and whether later lines could be effective even when earlier ones were not.
Patients and methods:
We retrospectively collected data f...
Background
Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have analyzed treatment pathways and outcomes of a single-institution series of advanced AC patients in order to provide insight into the...
709
Background: International guidelines suggest that RT dose escalation, intraoperative RT or brachytherapy could be considered for LARC pts with positive resection margins, pT4 or unresectable tumours after standard neoadjuvant CRT. However, data to support these approaches are scarce. The potential of systemic CT as salvage treatment after failu...
Purpose:
To evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC).
Materials and methods:
A systematic search of literature pertaining to...
Background:
Generic anticancer drugs represent an opportunity in terms of cost savings but there are some concerns about their tolerability. The safety profiles of generic versus branded oxaliplatin formulations have never been studied in detail.
Patients and methods:
We tested in vitro concentrations, stability and efficacy of branded versus ge...
Background:
Research biopsies are an increasingly important component of clinical trials, but there are concerns that biopsies may deter patients from participating in research.
Patients and methods:
Patients participating in a single-center study investigating the feasibility of molecular profiling in advanced gastrointestinal cancers were aske...
Introduction:
Blood perfusion of liver metastases can be non-invasively assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The aim of this study was to explore whether the ratio of hepatic arterial to total liver blood flow (Hepatic Perfusion Index-HPI) and the area under the enhancement curve (AUC) of selected liver areas...
To the Editor We read with interest the original investigation by Unger and colleagues,1 comparing the scientific impact, in terms of citation counts, of positive randomized clinical trials (RCTs) vs RCTs producing negative results, in the field of oncology. The amount of citations is a reasonable, “objective” measure to evaluate the impact of an R...
Seasonal variation of baseline diagnosis (or clinical suspect) of stage I-III colorectal cancer patients has been repeatedly reported as an independent variable influencing overall survival. However, data are conflicting and no information is available about such a rhythm in advanced stage patients. To test whether a circannual rhythm of efficacy o...
Serum marker evaluation is an easily available prognostic indicator that may help clinicians to discriminate patients with an aggressive disease; there are few and small-sized studies exploring the prognostic role of baseline carcinoembryonic antigen (CEA) values and their variations during first-line therapy, and even fewer data are available for...
Case:
Thrombocytopenic thrombotic purpura (TTP), a life-threatening event consisting of disseminated vascular thrombosis, has never been described before as a possible side effect of the anticancer drug pemetrexed. A 70 years old patient affected by a poorly differentiated non small cell lung cancer, subjected to his first pemetrexed administratio...
Insulinoma is a rare form of insulin-secreting pancreatic islet cell neuroendocrine (NE) tumor. The medical treatment of the malignant NE disease of the pancreas deeply changed in the last years, thanks to the introduction of new target molecules, as everolimus. Even if the exact mechanism is not actually known, one of the side effects of everolimu...
Background:
The management of advanced colorectal cancer patients differs among cancer centers. International guidelines recommend offering all the recognized active regimens in order to obtain survival advantage, but little information is given about the sequence and combination in which such regimens should be administered.
Case report:
We rep...
Background
The management of advanced colorectal cancer patients differs among cancer centers. International guidelines recommend offering all the recognized active regimens in order to obtain survival advantage, but little information is given about the sequence and combination in which such regimens should be administered.
Case report
We report...
Background:
The role of surgery for lung metastases (LM) secondary to colorectal cancer (CRC) remains controversial. The bulk of evidence is derived from single surgical series, hampering any definitive conclusions. The aim of this study was to compare the outcomes of CRC patients with LM submitted to surgery with those who were not.
Patients and...
Citations
... No TKIs-treated patients experienced treatment delays [40]. A recent Italian study presented at the World Conference on Lung Cancer (WCLC) 2021, reported a 4.4% delay in diagnostic, therapeutic, and palliative oncological procedures [41]. A total of 135 procedures were performed in 125 lung cancer patients, most including lung biopsies with diagnostic intent. ...
... All these considerations lead to the need of collecting observational data in routine clinical practice. Recent data reporting CT-related oral problems examined only specific CT regimens [22,23], tumors [24,25], or toxicities [26,27]. The lack of information from the patients' perspective on oral problems arising during the routine oncology practice [28], across a range of solid tumors and CT regimens, represented open questions which would be addressed through our prospective observational study. ...
... The indication of radiotherapy/chemoradiotherapy itself in metastatic tumors is debated, as well as its optimal administration schedule (timing and dose) [18,19]. Such complexity and lack of evidence lead to wide heterogeneity across national and international guidelines [20], and patients are currently managed on a case-by-case basis by multidisciplinary teams. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/751255441903628-1556124663616_Q64/Tugba-Telli.jpg)
... Also, initial PBTs have identified high and low risk subgroups of short and long survivors, among the participants in registration trials of first-line treatment for advanced CCA. PBTs were independent surrogate markers that serve as a summary variables to improve predictions of survival in comparison to clinical characteristics alone (13)(14)(15)(16). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/820448895967234-1572621668424_Q64/Massimiliano-Salati.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281133222235-1680271556153_Q64/Chiara-Braconi.jpg)
... der Versorgenden. Die Einbeziehung von PRO in die Versorgung onkologischer Patient*innen verbessert Patient*innenzufriedenheit und Lebensqualität[4,77] sowie deren Selbstwirksamkeit[2]. Die aktive Einbindung der Betroffenen in die Therapieentscheidung ("shared decision-making") und -durchführung verbessert ihre Einschätzung der Qualität von Kommunikation und Betreuung[32]. Der Deutsche Ethikrat hat 2016 das Patient*innenwohl als maßgebliches ethisches Leitprinzip in den Mittelpunkt gerückt. ...
... More recently, a panel of multiple combined genomic alterations comprising activating mutations of the MAPKs or PI3K/AKT axis, NTRK/ROS1/ALK/RET rearrangements, HER2 amplification or mutations, and MET amplification (the PRESSING panel), has been shown to be able to predict primary resistance to anti-EGFRs in RAS/BRAF WT mCRCs. 70 Additionally, a right-sided primary tumor location was found to be associated with resistance to anti-EGFRs, confirming previous literature evidence. Overall, the combined evaluation of the PRESSING panel and primary tumor location demonstrated the best predictive accuracy. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/327678218522625-1455135983602_Q64/Chiara-Cremolini.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/817635621085184-1571950931048_Q64/Federica-Morano.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272389166596119-1441954046450_Q64/Filippo-Pietrantonio.jpg)
... However, several reports have described patients with mCRC who achieved long-term survival after the resection of distant metastases [2][3][4]. Ottone et al. reported long-term survival in a patient after oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from CRC [5]. Fig. 2 Clinical course of the patient's metastases, surgeries, and other anticancer treatments. ...
... Так, в 2003 г. одобрен первый антагонист рецепторов нейрокинина-1 -апрепитант 1 . Его внедрение значительно повысило эффективность контроля тошноты и рвоты, ассоциированных с ХТ, и препарат включили в стандартные схемы противорвотной терапии [20,[24][25][26][27]. ...
... High concordance rates were observed between conventional methods and NGS for detection of EGFR, KRAS, ALK and ROS1, further confirming that high-quality sequencing data can ensure the accurate analysis and interpretation of NGS data. However, FFPE samples are more challenging than fresh samples to get high-quality sequencing data (Moorcraft et al. 2018). In resection samples, we found that predictors for high-quality sequencing data were samples with shorter storage time and lower DNA degradation. ...
... [2][3][4] Oxaliplatinand fluoropyrimidine-based chemotherapy is widely used in digestive tract cancer. [5][6][7] The risk of grade 3/4 neutropenia has been reported to range from 6.3% to 58%, [8][9][10][11] making it difficult to estimate the individual risk of neutropenia. ...
